SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

IN THE PRESS
Press Releases
Immunic, Inc. to Participate in Investor Conference in December
November 26, 2024
 · 
5 min read
Press Releases
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
November 14, 2024
 · 
9 min read
Press Releases
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
October 31, 2024
 · 
5 min read
Press Releases
Immunic to Participate in Industry, Scientific and Investor Conferences in November 2024
October 29, 2024
 · 
5 min read
Press Releases
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
October 23, 2024
 · 
10 min read
Press Releases
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
September 18, 2024
 · 
13 min read
Press Releases
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
September 4, 2024
 · 
10 min read
Press Releases
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September 2024
August 28, 2024
 · 
8 min read
Press Releases
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
August 1, 2024
 · 
5 min read
Press Releases
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 24, 2024
 · 
7 min read
Load More
JOBS